EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Nanomedicine orchestrated metabolic reprogramming of immune cells in antitumor immunity

Anqi Lin, Yuhong Chen, Jiwei Liu, Aimin Jiang, Weiliang Zhu, Quan Cheng, Jian Zhang, Qihang Yuan, Wenjun Mao, Peng Luo

Cancer Letters · 2026-09 · 656 · 218586

DOI: 10.1016/j.canlet.2026.218586 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Letters, 2026-09. Verfasst von Anqi Lin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Donghai County People's Hospital (Affiliated Kangda College of Nanjing Medical University), Department of Oncology, Zhujiang Hospital, Southern Medic…. Hauptthemen laut MEDLINE: Neoplasms, Nanomedicine. Die Arbeit nennt 181 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysregulation of immune cells within the tumor microenvironment represents a fundamental mechanism underlying tumor immune evasion. Nanomedicine, representing the interdisciplinary integration of nanotechnology and medicine, holds transformative potential for cancer immunotherapy. This narrative review demonstrates that by reprogramming four key metabolic domains-glucose metabolism, lipid metabolism, mitochondrial function, and iron metabolism-nanomedicine can achieve precise, multi-target regulation of core immune cell functions, including those of T cells, dendritic cells, and tumor-associated macrophages. Consequently, nanotherapeutics significantly enhance antitumor immunity through multiple mechanisms: increasing antigen presentation efficiency and T-cell activation, remodeling the immunosuppressive tumor microenvironment, normalizing aberrant tumor vasculature, alleviating hypoxia, and augmenting tumor cell immunogenicity. Furthermore, synergistic combination strategies employing nanotherapeutics alongside immune checkpoint inhibitors significantly improve therapeutic efficacy by optimizing drug delivery efficiency and targeting specificity, while simultaneously overcoming resistance to immune checkpoint inhibitors and mitigating systemic adverse reactions. Despite the remarkable preclinical potential of these approaches, critical knowledge and technological gaps remain, including incomplete elucidation of molecular mechanisms, insufficient optimization of biosafety profiles, suboptimal tumor-targeted delivery efficiency, and a lack of systematic integration with adjuvant therapies. Future efforts focused on advancing in-depth mechanistic research, designing advanced biomaterials, exploring rational combination regimens, and developing personalized treatment protocols will ultimately establish nanomedicine as a pivotal breakthrough in precision oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsNanomedicineHumansMetabolic ReprogrammingTumor MicroenvironmentAnimalsImmunotherapyTumor-Associated MacrophagesImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

Immune cell metabolic reprogrammingImmune checkpoint inhibitorsNanomedicineTumor immunologyTumor microenvironment

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Donghai County People's Hospital (Affiliated Kangda College of Nanjing Medical University), Department of Oncology, Zhujiang Hospital, Southern Medical University, Lianyungang, 222000, China; Department of Oncology, Zhu…
  • Department of Thoracic Surgery, Wuxi People's Hospital, Wuxi Medical Center, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Nanjing Medical University, Wuxi, 214023, China.
  • Department of Urology, Changhai Hospital, Naval Medical University (Second Military Medical University), Shanghai, China.
  • Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510282, China.
  • Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Hunan, China.
  • Department of General Surgery, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, 116011, China. Electronic address: qihangdy@163.com.

Zitieren

APA

Lin, A., Chen, Y., Liu, J., Jiang, A., Zhu, W., Cheng, Q., Zhang, J., Yuan, Q., Mao, W., & Luo, P. (2026). Nanomedicine orchestrated metabolic reprogramming of immune cells in antitumor immunity. Cancer Letters, 656, 218586. https://doi.org/10.1016/j.canlet.2026.218586

Vancouver

Lin A, Chen Y, Liu J, Jiang A, Zhu W, Cheng Q, et al. Nanomedicine orchestrated metabolic reprogramming of immune cells in antitumor immunity. Cancer Letters. 2026;656:218586. doi:10.1016/j.canlet.2026.218586

BibTeX
@article{Lin2026,
  author = {Lin, Anqi and Chen, Yuhong and Liu, Jiwei and Jiang, Aimin and Zhu, Weiliang and Cheng, Quan and Zhang, Jian and Yuan, Qihang and Mao, Wenjun and Luo, Peng},
  title = {Nanomedicine orchestrated metabolic reprogramming of immune cells in antitumor immunity},
  journal = {Cancer Letters},
  year = {2026},
  volume = {656},
  pages = {218586},
  doi = {10.1016/j.canlet.2026.218586}
}
Kostenlos starten →